-
Grazoprevir hydrate: HCV Research Workflows
2026-08-20
Grazoprevir hydrate, also known as MK-5172 hydrate, supports genotype-aware HCV replication studies through highly potent NS3/4A protease inhibition. This guide converts its pharmacology into practical dose-response, combination, resistance, and troubleshooting workflows for translational laboratories.
-
TAI-1 and the Next Logic of Mitotic Targeting
2026-08-20
TAI-1 is a potent Hec1 inhibitor that connects mitotic control, apoptotic cell death induction, and translational oncology strategy. This thought-leadership analysis places its Hec1-Nek2 mechanism alongside emerging evidence on replication-transcription conflicts after WEE1 inhibition, while defining practical validation, biomarker, combination, and preclinical development priorities.
-
FPH1 (BRD-6125): A Smarter Liver Assay Strategy
2026-08-19
FPH1 (BRD-6125) can be evaluated more rigorously by separating hepatocyte expansion from functional maturation. This guide connects primary human hepatocyte culture, iPSC-derived hepatocyte assays, and light-controlled gene-expression concepts without overstating the current evidence.
-
Silymarin: Research Uses, Mechanisms, and Limits
2026-08-19
Silymarin is a polyphenolic milk thistle extract used as a reference preparation in oxidative stress, cancer, antiviral, and metabolic research. Its mixture composition, low water solubility, and assay-dependent activity require careful controls and should not be interpreted as proof of clinical efficacy.
-
Entecavir (BMS200475): HBV Evidence
2026-08-18
Entecavir, also known as BMS200475, is a selective HBV DNA polymerase inhibitor that suppresses reverse transcription and viral DNA synthesis. Its strong activity against wild-type HBV, activity against selected lamivudine-resistant variants, and low long-term resistance rate support chronic hepatitis B infection therapy when treatment is clinically indicated.
-
Bifendate (DDB): Applied Liver Research Workflows
2026-08-18
Bifendate (DDB) supports practical studies of hepatic lipid accumulation, autophagy, and injury through coordinated cell-based and animal workflows. This guide combines formulation controls, flux-aware assay design, translational safety checks, and troubleshooting for more reproducible liver research.
-
Adefovir Dipivoxil in Chronic Hepatitis B
2026-08-17
The reference review established adefovir dipivoxil as a clinically useful nucleotide analog for chronic hepatitis B, emphasizing activity against both wild-type and lamivudine-resistant HBV, durable suppression, and relatively low resistance. Its practical significance lies in connecting the adefovir DNA polymerase inhibition pathway with evidence from heterogeneous patient populations, including HBeAg-positive, HBeAg-negative, decompensated, and transplant-associated disease.
-
Hydroxychloroquine Sulfate Protocol Guide
2026-08-17
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible option for experimental autophagy pathway modulation and toll-like receptor 7/9 signaling studies in autoimmune disease research. It is best suited to short-term, water-based workflows and should not be selected for protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.
-
Nelfinavir Mesylate: Reliable Cell Assays
2026-08-16
A scenario-based guide to using Nelfinavir Mesylate (SKU A3653) in HIV infection research, cell-viability studies, and ferroptosis-related workflows. It connects quantitative product data with practical controls for stock preparation, assay interpretation, and vendor selection.
-
Cisplatin (CDDP): From DNA Damage to Translation
2026-08-15
A translational framework for using Cisplatin and CDDP to connect DNA crosslinking, apoptosis, oxidative stress, xenograft response, and chemotherapy resistance studies with more decision-ready experimental strategies.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-08-14
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteasome response to ferroptotic stress. Its proteomic and genetic evidence shows that disrupting this pathway causes proteasome dysfunction, protein hyperubiquitylation, and greater ferroptosis sensitivity, while pharmacological DDI2 inhibition with nelfinavir produces a similar phenotype.
-
How SHH and FGF10 Shape Species-Specific Penile Development
2026-08-14
A 2025 Cells study identifies differential Shh, Fgf10, and Fgfr2 expression as a major determinant of why guinea pigs form an open urethral groove whereas mice primarily canalize the urethral plate. Comparative gene-expression analysis and genital-tubercle culture experiments provide a mechanistic framework for studying species-specific penile development and its relevance to congenital malformation research.
-
Salinomycin Workflows for HCC Research
2026-08-13
Build more informative hepatocellular carcinoma assays with Salinomycin, a polyether ionophore antibiotic that connects ion transport, ABC drug transporters, Wnt/β-catenin signaling, and apoptosis. This guide combines practical dosing, orthogonal readouts, controls, and troubleshooting for reproducible in vitro workflows.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-08-13
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteostasis response to ferroptosis. Its findings show that preserving proteasome function through the DDI2–NFE2L1 pathway limits ubiquitin accumulation and cell death, while pharmacological disruption with nelfinavir sensitizes cells to ferroptotic stress.
-
Dimethyloxalylglycine (DMOG) Workflow Guide
2026-08-12
Dimethyloxalylglycine (DMOG) provides a practical chemical method for inducing hypoxia-inducible factor stabilization in cell-based oxygen-sensing and hypoxia-response studies. It should be applied as a research reagent with appropriate vehicle, concentration, and endpoint controls, and is not intended for diagnostic, therapeutic, or medical use.